225 results about "Ribonucleotide" patented technology

The present disclosure relates to compositions and methods for separating and / or purifying polyribonucleotides. The polyribonucleotide may be separated from a mixture of polyribonucleotides with an oligonucleotide that hybridizes to a target region of the polyribonucleotide and be available for use as a therapeutic agent.

Provided in the present invention are a method for preparing a strand-specific library for the rapid detection of various types of RNAs, and a high-throughput sequencing method. A polyadenylic acid (poly A) tail is artificially added at the 3' terminal of various RNAs by using a poly A polymerase, and a single-stranded cDNA is synthesized using a poly-deoxythymidine ribonucleotide primer with deoxyuridine under the action of a reverse transcriptase. The obtained single-stranded cDNA molecule is subjected to a series of reactions, and the reaction product is finally amplified by means of PCR to obtain a strand-specific library of various types of RNAs. The library sample can be subjected to on-machine sequencing.

The invention relates to a preparation method of a binary guanidyl block copolymer (Poly-PEG-GUA) for nucleic acid transfection of human vascular endothelial cells (HUVEC). According to the invention, N-(2-(3-carbamyl guanidyl) ethyl) methacrylamide with different proportions is subjected to reversible addition-fragmentation chain transfer (RAFT) polymerization to polyethylene glycol modified 4-cyano-4-(phenyl thioformyl sulfenyl) valeric acid (PEG-CPADN), so that five kinds of binary guanidyl block copolymers with different molecular weights are constructed; the HUVEC gene and messenger ribonucleotide (EGFP-mRNA) of green fluorescent protein are assembled in the HUVEC for screening of transfection efficiency, and the optimal molecular weight for HUVEC transfection is optimized. Experimental results show that the Poly-PEG-GUA with the molecular weight of 53575 Daltons can be used for effectively delivering green fluorescent protein (EGFP) mRNA (messenger ribonucleic acid) to HUVEC (human umbilical vein endothelial cells), and the highest transfection efficiency is shown. The optimized Poly-PEG-GUA in the invention has a certain reference value for the research and development of subsequent cardiovascular transfection products.

This disclosure provides compositions, pharmaceutical preparations, and methods relating to circular polyribonucleotides encoding the expression of Varicella-Zoster Virus immunogens.

Provided herein are 5-fluorouracil derived cyclic deoxyribonucleotide compounds, their preparation and their uses, such as treating liver diseases or various types of cancer.

The invention discloses a method and application for enhancing cytidine production, and belongs to the field of genetic engineering and microbial engineering. The present invention knocks out cytidine deaminase gene cdd, uridine kinase gene udk, pyrimidine-specific ribonucleoside hydrolase gene rihB, nucleotide 5'-monophosphate nucleosidase gene ppnN, pyruvate oxidase gene poxB and integrates and expresses 5'-CTP diphosphohydrolase, orotate phosphoribosyltransferase, uridylate kinase mutant gene PyrH (R92G / D93G), as well as phosphoribosyl pyrophosphate synthetase gene prs, glucose-6-phosphate dehydrogenase gene zwf and 6-phosphogluconate dehydrogenase gene gnd, and constructs a recombinant Escherichia coli with enhanced cytidine synthesis ability, and the cytidine yield reaches 61.9g / L in a 30L fermenter without adding antibiotics and inducers, which can be used to realize the industrial production of cytidine and realize green biomanufacturing.

The invention provides a plant viral vector comprising a heterologous nucleotide sequence that encodes, or corresponds to the RNA sequence of a functional minimal miRNA precursor, wherein said RNA sequence consists of S1 that is of a length of 56-400 ribonucleotides and that comprises regions R1, R2, R3, R4 and R5 directly linked to each other as indicated in formula (i): (i) 5'-R1-R2-R3-R4-R5-3', wherein: - R1 consists of the RNA sequence of a strand of a basal stem (BS) structure, - R2 consists of the RNA sequence of a miRNA, - R3 comprises an RNA sequence that has a length of at least 8 nucleotides, - R4 consists of an RNA sequence that base pairs with the RNA sequence of R2 to form a miRNA / miRNA* duplex, - R5 consists of the RNA sequence complementary to R1 in the BS comprising R1, and wherein the RNA sequence S1 forms a stem-loop structure where the stem comprises regions R1, R2, R4 and R5 wherein region R1 base pairs with region R5 and region R2 base pairs with region R4, and the loop comprises a sequence of at least 4 contiguous nucleotides of region R3. The invention also provides a virus encoded by or comprising the viral vector, a plasmid comprising or encoding the viral vector, a bacterium comprising the plasmid, a plant comprising the viral vector, the virus or the bacterium, a plant extract from the plant, and a method for obtaining the plant and a method for obtaining the extract.

The present invention relates to CpG oligodeoxyribonucleotides with improved body immunity, combinations thereof with additional adjuvants, and uses of the CpG adjuvants or combinations thereof in various vaccine compositions. The CpG independently serves as an adjuvant or is combined with an existing marketed adjuvant for use, and the CpG has the very remarkable advantages that the immune effect is advanced, the immune effect is improved, the lasting period of the immune protection effect is longer, the potential anaphylactic reaction is lower and the like, is superior to a commercially available vaccine adjuvant or an adjuvant system, and is a very excellent effective component of the vaccine adjuvant or the vaccine adjuvant system.

Disclosed herein is a modified ribonucleotide comprising a nucleoside comprising 2′-O-acetylated ribose, and polyribonucleotides comprising the same. Also provided herein are compositions comprising a polyribonucleotide of the present disclosure and methods of making and using the same.

Disclosed herein include methods, compositions, and kits suitable for use in the measurement of the states of living cells across time and for use in the delivery of polyribonucleotides and circuits. There are provided, in some embodiments, RNA exporter proteins comprising an RNA-binding domain, a membrane-binding domain, and an interaction domain capable of nucleating self-assembly. Disclosed herein include polynucleotides encoding reporter RNA molecule(s) or cargo RNA molecule(s). In some embodiments, a plurality of RNA exporter proteins are capable of self-assembling into lipid-enveloped nanoparticles (LNs) secreted from a cell in which the RNA exporter proteins are expressed, thereby generating a population of LNs comprising exported reporter RNA molecule(s) or a fusogen and exported cargo RNA molecule(s). Disclosed herein include export modulator proteins capable of, e.g., enhancing or suppressing LN export.

The invention provides a viral vector comprising a heterologous nucleotide sequence that encodes or corresponds to an RNA sequence S1 that has a length of 52-350 ribonucleotides and that comprises regions R1, R2 and R3 directly linked to each other as indicated in formula (i):         (i)     5'-R1-R2-R3-3', wherein: - region R1 consists of the target site of a sRNA, - region R2 consists of an RNA sequence of 11 ribonucleotides, and - Region R3 consists of the RNA sequence of one or more siRNAs, wherein when R3 is formed by more than one siRNA sequence, the siRNA sequences are directly linked to each other. The invention also provides a virus encoded by or comprising the viral vector, a plasmid comprising or encoding the viral vector, a bacterium comprising the plasmid, a plant comprising the viral vector, the virus or the bacterium, a plant extract from the plant, and a method for obtaining the plant.

The invention provides a viral vector comprising a heterologous nucleotide sequence that encodes, or corresponds to the RNA sequence S1 that is of a length of 56-400 ribonucleotides and that comprises regions R1, R2, R3, R4 and R5 directly linked to each other as indicated in formula (i):         (i)     5'-R1-R2-R3-R4-R5-3', wherein: - R1 consists of the RNA sequence of a strand of a basal stem (BS) structure, - R2 consists of the RNA sequence of a miRNA, - R3 comprises an RNA sequence that has a length of at least 8 nucleotides, - R4 consists of an RNA sequence that base pairs with the RNA sequence of R2 to form a miRNA / miRNA* duplex, - R5 consists of the RNA sequence complementary to R1 in the BS comprising R1, and wherein the RNA sequence S1 forms a stem-loop structure where the stem comprises regions R1, R2, R4 and R5 wherein region R1 base pairs with region R5 and region R2 base pairs with region R4, and the loop comprises a sequence of at least 4 contiguous nucleotides of region R3. The invention also provides a virus encoded by or comprising the viral vector, a plasmid comprising or encoding the viral vector, a bacterium comprising the plasmid, a plant comprising the viral vector, the virus or the bacterium, a plant extract from the plant, and a method for obtaining the plant.

This invention relates generally to devices, systems, and methods for the preparation and processing of circular polyribonucleotides comprising the use of a pressurization device comprising a reservoir comprising (a) a filtrate chamber and a (b) waste collection chamber separated by (c) a filter; the reservoir further comprising (d) a removable cap in contact with a pressure inlet port; wherein the device is in fluidic communication with a positive pressure source.

In one aspect, the disclosed technology relates to nanopore sequencing with a polynucleotide including a plurality of ribonucleotides, wherein each ribonucleotide comprises a cyclic loop between two positions of the ribonucleotide, wherein the cyclic loop comprises a spacer or reporter moiety corresponding to the identity of the ribonucleotide, one or more linkers, and optionally one or more arresting constructs. The cyclic loop may be selectively cleaved in a ribose-mediated pathway to cause cleavage at the 5' P-O bond of the phosphate backbone.

Methods are provided for nucleic acid amplification using primers that contain DNA oligonucleotide segments and at least one ribonucleotide. In PCR reactions, this increases the amount of amplified product with each amplification cycle, resulting in greater sensitivity and speed than conventional PCR. In isothermal reactions, this reduces the time required to detect the target. Also provided are methods for monitoring amplification reactions using probes that contain ribonucleotides, without relying on the 5'-nuclease activity of DNA polymerase.

The present disclosure relates to a modified 5'UTR derived from an alphavirus, such as the Venezuelan equine encephalitis virus (VEEV) wild-type 5'UTR sequence of SEQ ID NO 1 modified at least by a first nucleotide insertion, such as ribonucleotide insertion, between position 3 and position 4 of the corresponding wild-type 5'UTR sequence of SEQ ID NO 1, wherein the first nucleotide insertion is preferably guanine, adenine or uracil.

The present disclosure describes methods, kits, and systems for digesting polyribonucleotides. The methods involve selectively forming an oligonucleotide (e.g., DNA: RNA or RNA: RNA) duplex with a single-stranded target RNA, and then selectively cleaving the target RNA into smaller fragments using a sequence-specific nuclease that acts only on the RNA within the duplex. Additional sequence-specific ribonucleases can be used to provide additional cleavage of the target RNA at a predetermined site. By forming double strands to increase the availability of nuclease enzymes that can be used to cleave the single-stranded target RNA and to selectively control the location at which the target RNA is cleaved, the target RNA can be digested into fragments within a controllable size range that are optimal for polynucleotide analysis, such as by liquid chromatography and mass spectrometry.

This disclosure provides a vaccine including a peptide with the amino acid sequence of SEQ ID NO:1; a nucleotide having the sequence of SEQ ID NO:2; or a ribonucleotide having the sequence of SEQ ID NO:3. In certain embodiments, the vaccine further comprises a buffer and / or an adjuvant.

Disclosed herein is a modified ribonucleotide comprising a nucleoside comprising 2′-O-acetylated ribose, and polyribonucleotides comprising the same. Also provided herein are compositions comprising a polyribonucleotide of the present disclosure and methods of making and using the same.

The present disclosure relates, generally, to compositions and methods for producing, purifying, and using circular RNA.

The invention discloses a lysosome targeted degradation system based on a DNA phase separation aggregate as well as a preparation method and application of the lysosome targeted degradation system, and belongs to the technical field of biological medicine and nanotechnology. The lysosome targeted degradation system based on the DNA phase separation aggregate comprises an RNA-DNA tetrahedral framework with a cohesive end, the RNA-DNA tetrahedral framework is formed by self-assembly of a core chain and an edge chain through complementary base pairing, the edge chain is a DNA-RNA chimeric oligonucleotide chain, and the DNA-RNA chimeric oligonucleotide chain is a DNA-RNA chimeric oligonucleotide chain. One or more sections of RNA ribonucleotide sequences which can be specifically recognized and cut by RNase H enzyme are embedded in the sequence, and the tail end of the RNA ribonucleotide sequence is modified with a cohesive tail end for driving phase separation and a cell membrane anchoring group; the RNA-DNA tetrahedral framework is modified with an aptamer of a targeted membrane protein. After entering cells, the system is subjected to liquid-liquid phase separation in a lysosome acid environment through interaction of cohesive ends, a micron-sized large-size aggregate is formed in situ, the residence time of a nano-drug in the lysosome is prolonged, and efficient degradation of target membrane protein is realized.

The present invention provides a DNA-targeting RNA comprising a single-guide RNA (sgRNA) and a ribonucleotide sequence rich in adenine ribonucleotide, and its use in gene editing, and a method for improving the efficiency of sgRNA-mediated gene editing, comprising a step of adding a ribonucleotide sequence rich in adenine ribonucleotide at 3′ end of the sgRNA.

The invention provides a chain-specific library preparation method and a high-throughput sequencing method for rapidly detecting multiple types of RNAs (Ribonucleic Acid). The method comprises the following steps: artificially adding poly A tails at 3'tail ends of multiple RNAs by utilizing poly A polymerase; meanwhile, a polydeoxythymine ribonucleotide primer with deoxyuracil is used for synthesizing single-stranded cDNA under the action of reverse transcriptase, obtained single-stranded cDNA molecules are subjected to a series of reactions and finally subjected to PCR amplification to obtain strand specific libraries of multiple types of RNA, and samples of the libraries can be subjected to computer sequencing.

The application discloses a single cell whole genome amplification sequencing method. The application comprises the following steps: 1) separating a single cell, adding a single cell lysis solution to sufficiently lyse the single cell and digest proteins combined on the genomic DNA; 2) using a Tn5 transposome with a specific adapter sequence to fragment the DNA, while adding adapters to both ends of the fragments; 3) after end repair, using a ribonuclease to cut modified ribonucleotide residues on the adapter sequence; 4) using the adapter sequence as a primer to linearly amplify the fragmented DNA by using a single primer PCR method; and 5) adding sequencing adapters to both ends of the DNA fragments by using a chain extension and PCR method to obtain a final sequencing library. The method disclosed by the application can amplify single cell whole genome DNA with high coverage, uniformity and fidelity, and simultaneously and accurately detect chromosomal copy number variation CNV and single nucleotide mutation SNV on a single cell genome.

To provide a food composition that does not contain animal-derived substances and that can be used as a food additive or flavoring to impart spice, umami, or meat seasoning to a food composition by utilizing fungi, yeast, and extracts of Ogataea pholymorpha. SOLUTION: The Ogataea polymorphic fungus yeast, extract, and biomass extract of the Ogataea polymorphic fungus of the present invention contain 0.03 to 3.1% w / w heme. They also contain 0.1 to 25% w / w amino acids. They also contain 0.1 to 2% w / w histidine. They are dissolved or formed by hydrolysis. The Ogataea polymorphic fungus of the present invention further contains proteins, amino acids, carbohydrates, and vitamins. They also contain glutathione. The present invention also relates to the production of recombinant heme proteins in methylotrophic yeast such as Ogataea polymorphic fungus. The Ogataea polymorphic fungus extract contains 0.007% or more 5' ribonucleotides. The 5' ribonucleotides are extracted from 5' GMP.

Disclosed herein is a modified ribonucleotide comprising a nucleoside comprising 2′-O-acetylated ribose, and polyribonucleotides comprising the same. Also provided herein are compositions comprising a polyribonucleotide of the present disclosure and methods of making and using the same.